Wednesday, December 1, 2021
HomeLatest NewsQuality/Safety NewsFDA approves new flu treatment

FDA approves new flu treatment

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. “This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical,” said FDA Commissioner Scott Gottlieb, MD.

Stay Connected

Unified Voice Newsletter

Events This Month

december

01dec11:00 am12:00 pmPrice Transparency and the No Surprise Act11:00 am - 12:00 pm CST Event Type :Education Events,Webinar

03dec8:00 am3:00 pmAdvances in Pediatric NeuroscienceVirtual Conference8:00 am - 3:00 pm CST Event Type :Community Events,Education Events

07dec1:00 pm2:00 pmOpioids and Treatment Services in South DakotaWebinar1:00 pm - 2:00 pm CST Event Type :Education Events,Webinar

08dec11:00 am12:00 pmPAMA Lab Test Private Payor Rate Reporting—What Clinical Labs Need to Know Now to Avoid Future PenaltiesSDAHO Webinar11:00 am - 12:00 pm CST Event Type :Education Events,Webinar

08dec12:00 pm1:00 pmThe Importance of Multidisciplinary Teams - How Project Firstline Can Support Your Facility’s Infection Prevention and Control Training NeedsAHA Webinar12:00 pm - 1:00 pm CST Event Type :Education Events,Webinar

X


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact